Innovent Biologics: The China Platform Is Real, but the Price Already Pre-Pays the Obesity Curve

That leads to the present placement. On trailing numbers, Innovent trades at about 10 times 2025 sales in HKD terms. That is much cheaper than the market currently pays for a pure option on a single global ADC success story such as Baili Tianheng, and far cheaper than Akeso’s revenue multiple, but it is still a demanding valuation for a company whose 2025 operating cash flow was heavily distorted by upfront receipts and whose flagship obesity asset is about to enter the hardest phase of the China GLP-1 market: the price war. The market is giving Innovent credit for being a real company and for having real optionality. That is fair. What it is also doing is pre-paying some of the success of mazdutide and of future licensing that has not yet been signed or converted into disclosed cash.

Vertical history and financial review

Innovent was founded in 2011 in Suzhou and came public on HKEX in October 2018 as one of the early beneficiaries of Hong Kong’s Chapter 18A regime for pre-revenue biotech listings. The IPO prospectus carried a maximum offer price of HK$14.00, and subsequent allotment materials show the offer price was HK$13.98 per share. Reuters reported at the time that the IPO valued the company at about US$2 billion and raised roughly US$421 million. The founding logic was straightforward: China had a fast-growing biologics market, but most innovation and most economics still sat with multinational drug companies. Innovent was built to close that gap with an integrated model spanning discovery, development, manufacturing, and commercialization.

Its first stage was the classic China biotech build-out: raise capital, build a pipeline, and prove that local biologics could be developed at globally acceptable quality. The second stage began when sintilimab turned the company from a pipeline story into a commercial one. That stage matters because it established the muscle that still differentiates Innovent today. Unlike many peers that remained asset-specific or licensing-dependent, Innovent built a large domestic field force, gained NRDL experience, expanded across tumor types, and layered in biosimilars, TKIs, and specialty products. By 2025 that machine had become broad enough that management could point to 18 approved products and a dual-engine portfolio rather than a single flagship drug.

The third stage was painful and reset valuation. China’s PD-1 field became crowded, repeated NRDL negotiations compressed price, and the U.S. option value in sintilimab collapsed after the FDA’s 2022 rejection of the lung-cancer filing. That episode still matters today because it changed how investors think about Chinese data packages, and it pushed Innovent harder toward either true global development or smarter partnering. It also made plain that sintilimab could be a strong Chinese product without ever becoming a global megabrand.

The fourth stage, which is still unfolding, began in 2025. Mazdutide won China approval for chronic weight management in June 2025, gained a type 2 diabetes approval in September 2025, and was highlighted by the company as an anchor growth asset in both fourth-quarter 2025 and first-quarter 2026 updates. At the same time, Innovent started converting its next-generation oncology and immunology pipeline into cross-border deals: Roche in early 2025, Takeda in October 2025, Lilly in February 2026, Pfizer in May 2026, Spero in July 2026, and a new China commercialization arrangement for Lilly’s Verzenios in June 2026. That is the transition point. Innovent is trying to become not just a Chinese seller of innovative drugs, but a recurring exporter of drug candidates and commercialization services.

A vertical read of the financials shows both the strength and the distortion. Revenue went from RMB9.42 billion in 2024 to RMB13.04 billion in 2025, while product revenue rose to RMB11.93 billion. Selling expense still consumed RMB5.71 billion, R&D was RMB2.62 billion, royalties and other related payments rose to RMB1.32 billion, and profit reached RMB813.6 million. The cost structure tells the story. Innovent is not yet a low-overhead royalty platform. It is a commercialization-heavy biopharma that continues to spend aggressively to support launches and pipeline depth. That spending looks reasonable when product revenue is growing above 40%, but it also means margins can compress quickly if a new franchise disappoints.

Cash quality is the key adjustment. The balance-sheet note shows contract liabilities rising from RMB824.2 million at the end of 2024 to RMB8.46 billion at the end of 2025, with the company explicitly stating it received RMB8.439 billion during 2025 for commercialization licenses related mainly to the October 2025 Takeda announcement. That pushed operating cash flow to RMB10.0 billion, while operating cash flow before working-capital movements was only RMB2.06 billion. Maintenance and growth capital spending remained manageable in pure plant terms, with property, plant and equipment purchases of RMB269.9 million and intangible-asset purchases of RMB413.4 million, but the broader point is that 2025 cash generation cannot be extrapolated as if it were all recurring product cash.

The price history follows the business history. The stock listed into a receptive biotech market, then rerated sharply during the China immuno-oncology wave. It derated as the PD-1 field commoditized and as the FDA rejection removed part of the international dream. The latest cycle has been a rerating on new facts rather than on hope alone: obesity launch, profitability, and hard-cash partnering. That is healthier than the earlier PD-1 optimism, but today’s valuation also embeds better execution than the 2022–2024 valuation trough ever assumed. The market is no longer pricing survival. It is pricing successful transformation.

Business model and moat

Innovent’s revenue machine has three layers. The base layer is domestic product sales, which supplied roughly 91% of 2025 revenue. The second layer is licensing and collaboration income, which was much smaller in P&L terms in 2025 but far larger in cash terms because of Takeda’s upfront. The third layer is platform value: the ability to use a large China commercial infrastructure and maturing antibody, ADC, and multispecific R&D capabilities to win either in-licensing rights or outbound deals. That third layer is why the company can take on products like Verzenios commercialization in mainland China while simultaneously out-licensing its own assets overseas.

The moat is real, but it is narrower than the bull case sometimes implies. The durable part is execution scale in China. Few Chinese biopharmas can launch at Innovent’s pace across oncology, cardiovascular-metabolic disease, autoimmune disease, and ophthalmology while sustaining multi-billion-renminbi product revenue. That shows up in the quarterly cadence: more than RMB2.7 billion of product revenue in second-quarter 2025, more than RMB3.3 billion in third-quarter 2025, about RMB3.3 billion in fourth-quarter 2025 despite NRDL-driven inventory price adjustments, and more than RMB3.8 billion in first-quarter 2026. A company cannot fake that level of commercialization.

The weaker part of the moat is product-level pricing power. Sintilimab remains important, but China’s domestic PD-1 market is crowded and repeated NRDL inclusion has turned immuno-oncology into a scale-and-access game more than a premium-pricing game. The company still described TYVYT as sustaining growth in 2025, and new indications such as fruquintinib combinations in renal-cell carcinoma help, but the economics of a Chinese PD-1 are now much more defensive than expansive. What funds Innovent today is not one oncology monoclonal antibody. It is the whole oncology franchise plus the ability to layer in new products faster than older ones decay.

Mazdutide is the opposite. It does not yet have a proven moat, only a plausible one. Its clinical profile is good enough to matter: the GLORY-1 obesity study reported 14.84% weight reduction from baseline at 48 weeks on 6 mg, and Nature papers from the diabetes program showed meaningful HbA1c reduction and weight loss versus placebo and dulaglutide. It also has a differentiating mechanism as a GLP-1/glucagon dual agonist rather than a plain semaglutide copy. But the market in front of it is becoming more brutal every quarter. That means the moat must come from brand, access, physician education, broad channel coverage, and speed of iteration, not simply from being first among domestic dual-agonists.

Governance is decent by Chinese biotech standards and appears reasonably aligned, though dilution is part of the history. The company remains founder-led under Chairman and Executive Director Dr. De-Chao Michael Yu, and 2025 included both a placing of ordinary shares and a Takeda-linked equity issuance that added to the capital base. That is not automatically a red flag in a biopharma platform that is still investing for growth, but it does mean shareholders have funded expansion partly through dilution as well as operations and deal cash. The stronger point in management’s favor is that the company promised EBITDA breakeven in 2025 and delivered non-IFRS EBITDA of RMB1.99 billion. The weaker point is that the cleanest test of management credibility will now be a much harder one: whether obesity becomes a recurring high-volume business without wrecking returns.

Industry and horizontal comparison

The industry backdrop is unusually favorable and unusually dangerous at the same time. In oncology, China’s innovative-drug market is large, reimbursement access has improved, and domestic companies can scale quickly once they crack the NRDL and hospital-access problem. In obesity and cardiometabolic disease, the patient pool is massive and still under-treated. A Lancet forecasting study placed China’s adult overweight-and-obesity population at roughly 402 million, and Reuters noted that more than 180 million Chinese suffer from obesity. Yet profit pools in Chinese pharmaceuticals do not sit where headline disease prevalence suggests. They sit where reimbursement, channel access, and pricing discipline allow them to sit. That is why obesity can be huge in epidemiology and still disappointing in equity value if pricing collapses.

The most important industry cycle for Innovent is a policy-and-technology cycle, not a macro cycle. Oncology earnings are shaped by approval wins, NRDL negotiation, provincial procurement, and competitive crowding. Obesity earnings are shaped by approval timing, retail self-pay demand, channel build-out, and then reimbursement or hospital access. When Reuters reported that mazdutide and ecnoglutide had passed the preliminary review for China’s 2026 reimbursement catalogue, the stock moved because investors immediately understood the trade-off: lower price, but wider public-hospital reach. The tension is structural, not temporary. Every successful metabolic drug in China will eventually face it.

The obesity battlefield is already crowded. Novo launched Wegovy in China in late 2024 and initially sold it out of pocket. Lilly brought Mounjaro into China and later got diabetes reimbursement. Pfizer’s partnered ecnoglutide won China approval for long-term weight management in March 2026. Hengrui’s ribupatide, a GLP-1/GIP dual agonist, has posted strong late-stage and follow-on data, while Novo’s partnered UBT251 from United Laboratories represents the next wave of “triple G” competition with 19.7% average weight loss at 24 weeks in a Chinese phase 2 trial. Against that backdrop, mazdutide’s opportunity is real, but the window for premium pricing is short.

Semaglutide’s China patent expiry raises the temperature further. Reuters reported in 2024 that the semaglutide patent would expire in China in 2026. A January 2026 legal analysis stated the core patent remained valid until March 20, 2026, and Reuters later reported that regulatory data protection runs into early 2027, delaying immediate generic launch despite the patent expiry. Jiuyuan had already filed for a Wegovy biosimilar by February 2026. This matters because it limits how much long-term value one can assign to plain GLP-1 economics in China. The market will keep moving toward next-generation agents, combinations, and sharper pricing. Mazdutide does at least offer mechanistic differentiation, but not immunity.

Against domestic peers, Innovent occupies a different niche. Akeso is the purer late-stage innovation and global-optionality story. Its 2025 commercial sales were RMB3.03 billion, far below Innovent’s RMB11.93 billion product revenue, but the market still values Akeso at roughly HK$90.8 billion because the market sees extraordinary value in ivonescimab and the broader bispecific pipeline. Innovent’s premium to Akeso on market cap reflects scale and commercialization breadth, not necessarily superior pipeline excitement. Junshi is closer in strategic ancestry, another Chinese PD-1 pioneer, but far smaller: 2025 revenue was about RMB2.50 billion and domestic toripalimab sales about RMB2.07 billion, leaving it much more exposed to a narrower product base. Baili Tianheng is the opposite extreme: the market affords it a very high sales multiple because it is being valued primarily as a global ADC option rather than as a mature broad-based commercial machine.

That peer set helps explain Innovent’s valuation. On trailing 2025 revenue, Innovent is cheaper than Akeso and dramatically cheaper than Baili Tianheng, but it is not cheap in an absolute sense. The market is rewarding Innovent for being a hybrid: more real revenue than the asset-optionality names, more pipeline monetization credibility than the pure domestic-commercial names. The risk is that hybrid businesses are hard to value when one leg is mature and pricing-led, and the other is early and expectation-led. Innovent’s valuation discount to the most speculative Chinese biotech winners is justified. A large further premium from here would need cleaner recurring metabolics revenue than has yet been disclosed.

Current fundamentals and valuation analysis

The last four disclosed quarters show a company with real momentum. Product revenue was over RMB2.7 billion in the second quarter of 2025, over RMB3.3 billion in the third quarter, about RMB3.3 billion in the fourth quarter despite channel inventory price adjustments linked to the 2026 NRDL, and over RMB3.8 billion in the first quarter of 2026. Management attributed the first-quarter 2026 strength to the dual-engine strategy: stronger oncology led by newly NRDL-included TKIs, and general-biomedicine growth led by mazdutide, tafolecimab, and teprotumumab N01. This is not a paper turnaround. Domestic demand is visibly running.

The more difficult question is what the market is trading now. It is trading one part fundamentals and one part narrative. The fundamentals are the 2025 revenue and profitability inflection, plus tangible growth in first-quarter 2026 product sales. The narrative is that mazdutide becomes a major obesity brand while Innovent continues to sign large out-licenses at a pace that proves global platform status. The facts support that narrative up to a point. But the stock also rose into a period when Chinese biotech dealmaking became fashionable again, and Reuters described 2025 Greater China licensing value as a record US$137.7 billion. A fashionable theme is not false. It is simply not enough on its own to underwrite a valuation.

The cleanest way to think about normalised earnings is to separate product economics from collaboration cash. Reported 2025 profit was RMB813.6 million. Reported 2025 operating cash flow was RMB10.0 billion, but that included a RMB7.64 billion contract-liability inflow. Reported purchases of property, plant and equipment were only RMB269.9 million, so the standard “owner earnings equals OCF minus maintenance capex” shortcut wildly overstates recurring earning power if one uses headline OCF. Using operating cash flow before working-capital movements of RMB2.06 billion and deducting property capex produces a rough owner-earnings figure around RMB1.8 billion, but even that still includes licensing-related economics and other items. For valuation, I therefore anchor on an even more conservative recurring base: normalized 2025 earnings power of roughly RMB0.5–0.8 billion from the domestic business before assigning separate value to obesity upside and ex-China pipeline optionality.

Mazdutide is the swing factor, so it needs a number. My base case values mazdutide at roughly HK$32–38 billion, equivalent to about HK$18–22 per Innovent share, using a risk-adjusted peak-sales framework rather than a clean DCF because the revenue curve is still too uncertain. The logic is this: China’s obesity population is enormous, but the realistic paying subset remains constrained by out-of-pocket affordability and reimbursement limits; GLP-1 sales on Alibaba and JD were about RMB1.4 billion in first-quarter 2026; pricing across the class is falling; and semaglutide generics should intensify the lower end of the market from 2027 onward. In my base case, mazdutide reaches peak China sales of about RMB6.5 billion, earns a 35% operating contribution at maturity after channel and pricing pressure, and receives a valuation multiple lower than what U.S. investors award global obesity leaders because China’s net pricing is weaker and competition more intense. In the bear case, peak sales are closer to RMB3.5–4.0 billion. In the bull case, if dual-agonist differentiation holds and diabetes reimbursement meaningfully widens access, RMB9–10 billion is attainable. Those numbers are lower than the most aggressive headline TAM stories, but they are more consistent with the way China drug economics usually evolve.

Sintilimab and the broader oncology base deserve a different treatment. The perioperative NSCLC phase 3 program that management earlier expected to read out around early 2026 had not publicly reported results by the base date; ClinicalTrials.gov still listed the primary completion for NCT05116462 as estimated September 30, 2026. That delay does not kill the case, but it matters because it pushes one of the cleaner near-term oncology catalysts to the right. The oncology base therefore should be valued as a durable but maturing cash franchise, not as a fresh multiple-expansion engine. I assume the whole oncology and specialty-commercial portfolio can still grow mid-teens for the next two years as new products offset PD-1 pricing erosion, but I do not assume sintilimab itself regains scarcity economics.

The absolute valuation framework below is a sum-of-the-parts exercise expressed in per-share HKD. It is valuation-scenario analysis within a research framework, not investment advice.

The table’s message is simple. Innovent is no longer cheap enough for investors to ignore execution risk, but it is not priced at fantasy either. The stock is roughly discounting a base case in which the domestic business keeps compounding and mazdutide becomes meaningful, but not dominant, before the market structure worsens. That is why valuation feels fair rather than compelling.

The margin-of-safety check is not generous. Current price is above the value implied by the conservative scenario, so margin of safety is not zero but not obvious. The most fragile assumption in my base case is not oncology. It is mazdutide net pricing. If I cut the mazdutide value contribution in the base case by 30%, base fair value falls from around HK$99 to around HK$92, which leaves little upside from the current price. If earnings were flat for three years and the stock merely held today’s price, the annualised return would be negligible and not much better than cash. This is a good company at a much more debatable price than it was before the 2025–2026 rerating. Margin-of-safety sufficiency verdict: not obvious.

Cross-synthesis summary

Innovent’s real achievement is not that it discovered a PD-1 or launched a GLP-1-class obesity therapy. Many companies can produce one successful drug. Innovent proved something harder: it built an operating system. Over roughly a decade it went from a funded biotech idea to a company that can manufacture at scale, win reimbursement, launch across multiple therapeutic areas, and convince global majors to write large checks for pipeline access. That capability did not come from luck alone. It came from management’s consistent preference for integration over narrow specialization. The company chose to build sales infrastructure early, chose to keep investing through the biotech down-cycle, and then chose to monetize its science through partnerships only after it had enough credibility to negotiate from strength.

The question for the next stage is whether those same strengths still map cleanly onto the most important battleground, which is no longer PD-1. In obesity, commercialization scale does help. Local channel knowledge does help. Broad hospital and retail access does help. But the product category is moving very fast toward commoditization at the low end and toward efficacy arms races at the high end. Novo is cutting price. Lilly is on reimbursement for diabetes. Pfizer now has ecnoglutide approved for weight management in China. Hengrui and United Labs are pushing dual- and triple-agonist programs. Semaglutide’s key China patent has already expired, and the only thing slowing generic commercialization is regulatory data protection. That means Innovent’s obesity franchise will probably create real revenue; the harder question is what portion of that revenue remains economically attractive after 2027.

That is why oncology still matters so much. The market sometimes treats oncology as the old story and obesity as the new one. In business terms, that is wrong. Oncology is still the funding base. The first-quarter 2026 update explicitly tied product growth to both oncology and general biomedicine, highlighting rapid uptake of five TKIs newly included in the NRDL. Innovent’s oncology position is not glamorous, but it remains strategically important precisely because it absorbs the early volatility of newer launches. What looks like a broad “Innovent moat” is really the combination of a maturing oncology-commercial machine and a management team willing to borrow that machine’s fixed-cost base for younger franchises.

The current valuation is therefore paying partly for what Innovent has already proved and partly for what it has not. It rewards past success in building a rare Chinese biopharma platform. It also pre-spends some future success in obesity and in outbound dealmaking. The market’s biggest likely misjudgment is not on whether Innovent is a real company. That debate is over. The likely misjudgment is on earnings cleanliness. A year in which contract liabilities rose by RMB7.64 billion after a major upfront cannot be read like a year in which the core business alone suddenly became a cash geyser. Investors who do not normalize that cash-flow picture risk overestimating how self-funding the platform already is.

For the next year, the critical variables are mazdutide sales disclosure, H1 2026 profitability quality, and whether the market gets visible evidence that obesity revenue is broadening beyond a launch-quarter spike. For the next three years, the critical variables are the pace of obesity price compression, the extent of diabetes reimbursement support, and whether one or more global pipeline assets such as IBI343 or IBI363 convert from promising data into late-stage, monetizable franchises. For the next five years, the decisive issue is whether Innovent becomes a durable dual-core company or whether oncology matures just as obesity commoditizes, leaving the stock valued as a “good Chinese pharma” rather than as a re-rated global platform.

Bull and bear reasons

The bull case starts with scale: Innovent generated RMB11.93 billion of product revenue in 2025 and more than RMB3.8 billion in first-quarter 2026, a revenue base none of its most comparable Chinese biotech peers can match.

A second bull reason is that the company has already turned pipeline optionality into signed cash, most clearly the Takeda upfront that shows up as RMB8.439 billion received in advance in the 2025 accounts.

A third bull reason is that mazdutide is clinically credible and commercially relevant, with obesity approval in June 2025, diabetes approval in September 2025, and continuing management emphasis as an anchor asset in 2026 updates.

A fourth bull reason is operating leverage. Selling expense as a share of total revenue fell from 46.1% in 2024 to 43.8% in 2025 even while Innovent funded multiple launches, showing that the platform can scale.

The bear case starts with price. At roughly 10 times trailing sales, the stock already discounts a substantial amount of successful obesity ramp and continued platform monetization.

A second bear reason is earnings quality. 2025 operating cash flow was dominated by contract-liability inflows, so the headline cash number overstates recurring business cash generation.

A third bear reason is that the obesity market is about to get much nastier: Novo and Lilly have already cut prices in China, semaglutide’s core patent expired in March 2026, and rival next-generation assets from Pfizer, Hengrui, and United Labs are advancing.

A fourth bear reason is that one of the cleaner near-term oncology catalysts slipped. The perioperative NSCLC phase 3 readout expected around early 2026 had still not been publicly reported by late July 2026, and the trial registry still showed primary completion estimated for late September 2026.

A fifth bear reason is that much of the premium now rests on dealmaking continuing. Lilly is effective, Pfizer is announced, Spero is announced, but future deals not yet signed cannot be capitalized as if they already exist.

Pre-mortem

The most likely 50% drawdown script is an obesity disappointment wrapped inside a valuation compression. Suppose by 2027 semaglutide copies and lower-priced branded GLP-1s pull the whole category down faster than expected, mazdutide fails to sustain premium positioning, and annualized obesity revenue stalls below RMB3.5 billion instead of moving toward the RMB6–10 billion range the market hopes for. At the same time, investors realize 2025 cash flow was largely deal-cash timing rather than recurring operations. The multiple could compress from around 10 times sales toward 5–6 times sales, taking the stock into the HK$40s even if the broader company remains profitable.

A second script is an oncology-optionality miss. The perioperative NSCLC program slips again or underwhelms, IBI343 or IBI363 fail to produce the global data needed for a premium transaction or late-stage confidence, and licensing momentum slows materially after the burst of 2025–2026 deals. In that case the market stops valuing Innovent as a pipeline-export platform and re-rates it as a good but ordinary China commercial biopharma. A stock that is fair at around HK$90 in a platform narrative can become a HK$50–60 stock in a domestic-pharma narrative without any collapse in the core business.

Final research conclusion

Innovent is a serious company. The domestic commercial base is real, the management team has already delivered more than one difficult transition, and the company has reached a point where global partners are validating the pipeline with large contractual commitments. That is a much stronger foundation than most Chinese biotech stories ever achieve. The problem is not quality. The problem is that the current stock price already recognizes a large part of that quality and has started to capitalize future obesity and pipeline success that still needs proof.

I would own Innovent more readily at a lower price or with one more turn of evidence. The cleanest thing that could change my mind positively would be hard disclosure on mazdutide’s net sales run-rate and mix, especially evidence that early uptake survives price normalization and that diabetes reimbursement broadens access without crushing realized economics. The main thing that would change my mind negatively would be the opposite: obesity revenue growth that looks strong only in gross launch terms while margins and realized pricing deteriorate too quickly.

【Company-profile scores】

• Fundamental quality: high
• Growth: high
• Moat: medium
• Financial soundness: strong
• Management credibility: high
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Strong China commercial platform and real obesity upside, but current price already discounts much of the second growth curve before economics are fully proven.
• 【Ideal Buy Price】60–66 HKD Basis: at least 20% below my conservative value range of HK$78–82 per share, to compensate for obesity pricing risk and the low quality of headline 2025 cash flow.
• Acceptable hold price: 82–112 HKD
• Clearly overvalued price: 136 HKD and above
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A price in the mid-60s, or a later entry at a higher price backed by clean disclosed mazdutide economics and recurring earnings quality, would improve the risk-reward.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about -3% to 0%; base about 3% to 5%; optimistic about 10% to 12%, using a three-year framing from HK$89.35 to the scenario value ranges.
• Max-loss risk: about 45%–55% if obesity economics disappoint and the market re-rates Innovent from platform-biopharma to ordinary China pharma on 5–6 times sales.
• Reassessment-trigger signals: mazdutide growth below expectations for two consecutive reporting periods; contract-liability normalization revealing weak underlying cash generation; perioperative NSCLC or other late-stage readouts slipping materially again; clear acceleration of semaglutide/generic price pressure; absence of meaningful new pipeline monetization by 2027.

【Valuation Range】

• current: 89.35 (close as of 2026-07-27)
• bear (conservative · ideal buy zone): [60, 66]
• base (fair · acceptable hold zone): [82, 112]
• bull (optimistic · above the clearly-overvalued line): [136, 150]

Key data tables

The table shows why the stock rerated and why investors should still normalize the numbers. Revenue scale and EBITDA are undeniably better. Cash flow is also undeniably less clean than the headline suggests.

This quarterly sequence matters more than management adjectives. It shows acceleration before any H1 2026 full financials are available, and it shows that the general-biomedicine franchise is already large enough to affect group growth visibly.

Research uncertainties

The biggest blind spot is mazdutide’s actual net sales and gross-to-net evolution. Innovent has highlighted the asset repeatedly, but as of the base date it had not publicly disclosed a clean standalone sales figure in filings I could verify.

A second uncertainty is how much of the Lilly 2026 upfront had been received in cash by July 28, 2026. The collaboration had become effective, but H1 2026 financial statements were not yet published.

A third uncertainty is the exact upfront amount in the Spero deal; public materials available in this research set clearly stated total deal value and royalties but not the upfront amount itself.

A fourth uncertainty is the exact 2025 product-sales contribution of sintilimab. Innovent described TYVYT as sustaining growth, but it did not disclose a clear line-item revenue figure in the primary materials I reviewed.

Sources

Primary sources used in this report were Innovent’s 2025 annual report and annual-results materials, HKEX announcement history, quarterly product-revenue updates, the 2025 annual-results presentation, and ClinicalTrials.gov for the perioperative NSCLC study timeline.

Secondary sources used for current market data, peer context, pricing and competitive dynamics included Reuters, Google Finance, MarketWatch, FT, Investing.com, peer annual-result releases, and selected specialist trade coverage where primary detail was not public.

Other tickers mentioned

• 9926.HK: Akeso, the closest Hong Kong-listed China biotech peer for platform optionality and premium pipeline valuation
• 688180.SHG: Junshi Biosciences, another China PD-1 pioneer with a smaller commercial base
• 688506.SHG: Baili Tianheng, a useful benchmark for how the market prices global ADC optionality in China
• LLY.US: Eli Lilly, Innovent’s long-term partner and the global obesity reference point
• NVO.US: Novo Nordisk, the incumbent global GLP-1 leader and the clearest signal on China obesity price pressure
• 1276.HK: Hengrui Pharma, advancing ribupatide and representing next-generation domestic metabolic competition
• 3933.HK: United Laboratories, partner on UBT251 and a source of triple-agonist pressure in China obesity
• PFE.US: Pfizer, Innovent’s 2026 oncology-partnership counterparty and also a China obesity competitor through ecnoglutide
• SPRO.US: Spero Therapeutics, counterparty in the July 2026 IBI355 licensing deal

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.